Berberine (CAS 2086-83-1): AMPK Activator for Metabolic & Inflammation Research

Executive Summary: Berberine is a plant-derived isoquinoline alkaloid, primarily acting through activation of AMP-activated protein kinase (AMPK) and modulation of metabolic signaling cascades. It upregulates low-density lipoprotein receptor (LDLR) expression in hepatoma cells in a dose-dependent manner (maximal at 15 μg/mL) [APExBIO]. Oral administration in hyperlipidemic hamsters at 50–100 mg/kg/day significantly reduces serum total and LDL cholesterol within 10 days, correlating with increased hepatic LDLR [Li et al., 2025]. Berberine displays anti-inflammatory activity via downregulation of proinflammatory cytokines and regulation of the NLRP3 inflammasome. It is insoluble in water and ethanol, but dissolves ≥14.95 mg/mL in DMSO at 37°C. APExBIO provides Berberine (N1368) as a standardized tool for metabolic disease, inflammation, and cardiovascular research.

Biological Rationale

Berberine is an isoquinoline alkaloid isolated from Cortex Phellodendri Chinensis and related plants. Its molecular formula is C₂₀H₁₈NO₄; molecular weight is 336.36 g/mol [APExBIO]. Berberine’s primary research applications arise from its ability to activate AMPK, a master regulator of cellular energy homeostasis. AMPK activation triggers downstream pathways controlling glucose uptake, fatty acid oxidation, and lipid metabolism [balaglitazone.com]. Furthermore, Berberine modulates inflammation by impacting NLRP3 inflammasome activation, a key mediator of sterile inflammation and pyroptosis [Li et al., 2025]. This dual action—metabolic regulation and inflammation attenuation—distinguishes Berberine from other metabolic agents and underpins its use in models of diabetes, obesity, cardiovascular disease, and acute kidney injury.

Mechanism of Action of Berberine (CAS 2086-83-1)

Berberine’s primary molecular mechanism is the activation of AMP-activated protein kinase (AMPK). Upon cellular uptake, Berberine increases the AMP/ATP ratio, directly activating AMPK. AMPK phosphorylates key targets, including acetyl-CoA carboxylase (ACC), resulting in increased fatty acid oxidation and reduced lipid synthesis [glucagon-19-29-human.com]. In human hepatoma cell lines (HepG2, Bel-7402), Berberine upregulates LDLR mRNA and protein expression in a dose-dependent manner, with maximal effects at 15 μg/mL [APExBIO]. This upregulation increases cellular LDL uptake and reduces circulating cholesterol.

Berberine also inhibits proinflammatory signaling. It suppresses the activation of the NLRP3 inflammasome, a cytosolic protein complex that mediates caspase-1 activation and IL-1β/IL-18 maturation. In models of acute kidney injury (AKI), inflammasome inhibition by Berberine reduces pyroptosis and tissue damage [Li et al., 2025]. These effects are independent of direct cGAS-STING pathway suppression, making Berberine a unique dual-action modulator [adrenorphin.net]—clarifying recent mechanistic debates.

Evidence & Benchmarks

• Berberine upregulates LDL receptor (LDLR) mRNA and protein in HepG2 and Bel-7402 cells, with maximal induction at 15 μg/mL and dose-dependence confirmed by RT-qPCR and western blot (APExBIO).
• Oral Berberine at 50 or 100 mg/kg/day reduces serum total cholesterol and LDL cholesterol in hyperlipidemic hamsters after 10 days, with increased hepatic LDLR expression (dose- and time-dependent) (Li et al., 2025).
• Berberine inhibits NLRP3 inflammasome activation and reduces IL-1β/IL-18 release in AKI models, attenuating inflammation and improving survival (Li et al., 2025).
• Berberine displays negligible solubility in water and ethanol, but achieves ≥14.95 mg/mL solubility in DMSO at 37°C, facilitating cellular and animal studies (APExBIO).
• AMPK-dependent and independent mechanisms underpin Berberine’s metabolic and anti-inflammatory actions, as reviewed in multiple translational research guides (glucagon-19-29-human.com).

This article extends prior guides (e.g., adrenorphin.net) by providing updated benchmarks for LDLR upregulation and NLRP3 suppression under defined experimental conditions.

Applications, Limits & Misconceptions

Berberine is widely used in metabolic disease research, including diabetes, obesity, and cardiovascular models. It is also employed in acute inflammation and kidney injury studies due to its impact on inflammasome pathways. Berberine’s AMPK activation is leveraged to study energy metabolism, lipid homeostasis, and gluconeogenesis suppression [glucagon-19-29-human.com].

Common Pitfalls or Misconceptions

• Misconception: Berberine is water-soluble. Fact: It is insoluble in water and ethanol; optimal solubility requires DMSO and warming to 37°C [APExBIO].
• Pitfall: Assuming all anti-inflammatory effects are AMPK-mediated. Fact: Berberine also directly modulates the NLRP3 inflammasome independently of AMPK [Li et al., 2025].
• Limit: Not all cell types or animal models respond equally; efficacy and pathway engagement may vary by tissue and species [adrenorphin.net].
• Misconception: Berberine is suitable for long-term stock solutions. Fact: Solutions should be stored below -20°C and used promptly; prolonged storage reduces potency [APExBIO].
• Limit: Clinical translation is under investigation; most claims are based on preclinical or animal data.

Workflow Integration & Parameters

APExBIO’s Berberine (CAS 2086-83-1, N1368) is provided as a solid, recommended for storage at -20°C, protected from moisture and heat. For in vitro use, dissolve in DMSO to ≥14.95 mg/mL; warming to 37°C or ultrasound can aid dissolution. For cellular assays, concentrations of 5–15 μg/mL have demonstrated maximal LDLR induction in HepG2 and Bel-7402 cells. In animal models, oral doses of 50–100 mg/kg/day are standard for lipid metabolism studies in rodents. Berberine is not suitable for aqueous formulations without solubilizing agents.

For advanced protocols, see adrenorphin.net, which details troubleshooting and use-case adaptations. This article clarifies dosing windows and storage parameters, updating previous practical guides.

Conclusion & Outlook

Berberine (CAS 2086-83-1) is a rigorously validated AMPK activator and inflammation modulator. Its dual-action profile—upregulation of LDL receptors and attenuation of NLRP3 inflammasome signaling—positions it as a cornerstone tool in metabolic and inflammation research. APExBIO’s standardized N1368 Berberine kit ensures reproducibility and reliability for preclinical workflows. As ongoing research clarifies clinical translation, Berberine remains a benchmark for mechanistic and translational studies in metabolic disease and inflammatory models. For purchase and detailed specifications, see Berberine (CAS 2086-83-1) from APExBIO.